Spinal Muscular Atrophy Market Analysis, Size, Share & Growth Forecast 2026–2034

Nusinersen NURTURE Pre-Symptomatic SMA Treatment Achieving Near-Normal Motor Milestone Development Has Established That Early Treatment Before Motor Neuron Loss Produces Dramatically Superior Outcomes to Symptomatic Treatment Initiation.Roche's risdiplam Evrysdi achieved 98% of patients maintaining or improving HFMSE scores in FIREFISH 2 in SMA Type 2 and 75% of late-onset patients achieving 3-point HFMSE improvement in SUNFISH, with the critical advantage of daily oral administration at home rather than the 4-monthly intrathecal injections required for nusinersen or the single intravenous infusion requiring hospital admission for onasemnogene. Prescriber preference for risdiplam has grown substantially in the treatment-naive SMA population as the oral route enables initiation in community settings without the procedural risk of lumbar puncture and without the USD 2.1 million one-time cost of gene therapy for patients with later-onset disease. The competitive landscape between three approved SMA therapies has driven Biogen and Novartis to develop SMA RNA splicing back-up compounds and next-generation formulations while health technology assessments increasingly favour risdiplam's combination of efficacy, tolerability, and administration convenience.

Zolgensma One-Time AAV9 SMN1 Gene Replacement in Pre-Symptomatic SMA Achieving 90 Percent Independent Sitting and 77 Percent Independent Standing at 24 Months Has Demonstrated That the One-Time Gene Therapy Before Motor Neuron Depletion Can Approach Normal Motor Development.The NURTURE trial treated 25 SMA infants before symptom onset with nusinersen identified through genetic screening, achieving sitting, standing, and walking independently in 100% of Type 1 and 2 genotype patients at age 5, demonstrating that presymptomatic treatment can prevent the devastating motor neuron loss that otherwise defines SMA. Newborn screening for SMA is now implemented in 42 US states, Canada, Germany, Austria, and Taiwan, creating a diagnostic infrastructure that enables gene therapy or SMN-targeting drug initiation before any motor neuron death occurs. The long-term durability of presymptomatic gene therapy benefit with Zolgensma is being monitored through RAINIER registry data, as SMA patients treated in infancy approach school age without significant motor neuron disease, raising optimism that early treatment may produce functionally curative outcomes.

Risdiplam Oral SMN2 Splicing Modifier FIREFISH and SUNFISH Demonstrating Motor Milestone Improvement Across SMA1 and SMA2 Has Provided the Oral Treatment Alternative to Intrathecal Nusinersen That Patients and Caregivers Prefer for the Simplified Administration Route.The oldest START trial patients treated with onasemnogene abeparvovec are approaching 8-9 years of follow-up, and Novartis's RESTORE registry is prospectively monitoring motor function, pulmonary outcomes, and adverse events in the global commercial cohort to identify late signal changes. Single-case reports of liver toxicity years after onasemnogene infusion have raised vigilance for late adverse events in a gene therapy exposed population that will be monitored for decades, and the mechanism of AAV integration events with theoretical genotoxic risk requires long-duration surveillance. The question of retreatment in patients who lose AAV9 transgene expression due to liver growth dilution in children treated as infants is being addressed by clinical programmes evaluating re-dosing strategies under immunosuppression and by next-generation gene therapy vectors with integration mechanisms designed for durable expression in dividing cells.

For related market intelligence, see the Rare Disease Drug Market.